Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 2/2018

01-06-2018 | Overactive Bladder (U Lee and S Adelstein, Section Editors)

Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA

Authors: Anna C. Kirby, Elizabeth S. Kellogg

Published in: Current Bladder Dysfunction Reports | Issue 2/2018

Login to get access

Abstract

Purpose of Review

To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB).

Recent findings

The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications.

Summary

Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.
Literature
1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMed
2.
•• Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A. Society of Urodynamics FPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. The most up to date guidelines regarding OAB diagnosis and treatment. CrossRefPubMed
3.
Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.CrossRefPubMed
4.
Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–8.CrossRefPubMed
5.
Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29(7):1267–71.CrossRefPubMed
6.
Elterman DS, Chughtai B, Vertosick E, Thomas D, Eastham J, Sandhu J. Trends and clinical practice patterns of sacral neuromodulation for overactive bladder. Female Pelvic Med Reconstr Surg 2017, 1.
7.
Laudano MA, Seklehner S, Sandhu J, Reynolds WS, Garrett KA, Milsom JW, et al. Disparities in the use of sacral neuromodulation among medicare beneficiaries. J Urol. 2015;194(2):449–53.CrossRefPubMed
8.
Withington J, Hirji S, Sahai A. The changing face of urinary continence surgery in England: a perspective from the hospital episode statistics database. BJU Int. 2014;114(2):268–77.CrossRefPubMed
9.
Suskind AM, Dunn RL, Kaufman SR, DeLancey JO, Clemens JQ, Stoffel JT, et al. Understanding the dissemination of sacral neuromodulation. Surg Innov. 2013;20(6):625–30.CrossRefPubMedPubMedCentral
10.
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.CrossRefPubMed
11.
Wolff EM PS, Odem-Davis K, Kirby AC. Modern practice patterns in women treated for non-neurogenic overactive bladder: how quickly do patients progress to third-line therapy. Female Pelvic Med Reconstr Surg. 2017;23(5S Abstracts).
12.
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy of overactive bladder in a practice with multiple subspecialty providers: are we doing enough? J Urol. 2017;197:e528–9.CrossRef
13.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2S):S216–S23.CrossRefPubMed
14.
Minassian VA, Yan X, Lichtenfeld MJ, Sun H, Stewart WF. The iceberg of health care utilization in women with urinary incontinence. Int Urogynecol J. 2012;23(8):1087–93.CrossRefPubMedPubMedCentral
15.
Goldman HB, Anger JT, Esinduy CB, Zou KH, Russell D, Luo X, et al. Real-world patterns of care for the overactive bladder syndrome in the United States. Urology. 2016;87:64–9.CrossRefPubMed
16.
Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65(3):309–14.CrossRefPubMed
17.
Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health. 2005;8(4):495–505.CrossRefPubMed
18.
Firoozi F, Gill B, Ingber MS, Moore CK, Rackley RR, Goldman HB, et al. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged. J Urol. 2013;190(2):594–7.CrossRefPubMed
19.
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99.CrossRefPubMed
20.
•• Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. The largest RCT comparing sacral neuromodulation with onabotultinumtoxinA performed at multiple centers by the Pelvic FLoor Disorders Network. CrossRefPubMedPubMedCentral
21.
•• Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. This study changes how we evaluate side effects of anticholinergic medications for our patients. Whereas previously we considered side effects to be potentially bothersome but reversible with cessation of antimuscarinic medications, we now have to counsel our patients regfarding the potential increased use of dementia with cumulative use. CrossRefPubMedPubMedCentral
22.
Committee AUSG. AUGS Consensus Statement: Association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–8.
23.
• Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13. The largest RCT comparing antimuscarinic medications to onabotulinumtoxinA for OAB, performed at multiple sites by the Pelvic Floor Disorders Network. CrossRefPubMedPubMedCentral
24.
•• Carter-Brooks CM, Shepherd J. A cost-effectiveness analysis of botox botulinum-A toxin as first-line treatment for overactive bladder. Female Pelvic Med Reconstr Surg. 2017;23(5S Abstracts):S17–75. AUGS abstract suggesting onabotulinumtoxinA might be cost-effective as a treatment for any patients with OAB, not just patients with refractory OAB.
25.
Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J. 2015;9(7–8):242–7.CrossRefPubMedPubMedCentral
26.
Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54.CrossRefPubMed
27.
Bertapelle MP, Vottero M, Popolo GD, Mencarini M, Ostardo E, Spinelli M, et al. Sacral neuromodulation and botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109–17.CrossRefPubMed
28.
Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210–6.CrossRefPubMed
Metadata
Title
Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA
Authors
Anna C. Kirby
Elizabeth S. Kellogg
Publication date
01-06-2018
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 2/2018
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-018-0462-7

Other articles of this Issue 2/2018

Current Bladder Dysfunction Reports 2/2018 Go to the issue

Overactive Bladder (U Lee and S Adelstein, Section Editors)

Insight Into the Central Control of Overactive Bladder Symptoms by Functional Brain Imaging

Overactive Bladder (U Lee and S Adelstein, Section Editors)

Management of Overactive Bladder in Children

Stress Incontinence and Prolapse (S Reynolds, Section Editor)

Stress Urinary Incontinence in Women with Neurogenic Lower Urinary Tract Dysfunction

Neurogenic Bladder (C Powell, Section Editor)

Urologic Applications of the Microbiota in Multiple Sclerosis

Pediatric Voiding Dysfunction (Douglas Clayton and John Thomas, Section Editors)

Non-invasive Testing and Its Role in Diagnosis and Management of Children With Voiding Dysfunction

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Prostate Artery Embolization: Current Status 2018